Testing a radioactive therapy combined with standard medication for neuroendocrine tumors

This trial is testing Lutetium (177Lu) Oxodotreotide Injection — a radioactive medication that targets cancer cells — to see if combining it with standard-dose medication works better than using a higher dose of the standard medication alone. The study focuses on people with advanced neuroendocrine tumors (slow-growing cancers that start in hormone-producing cells) that have spread or cannot be surgically removed. Researchers want to understand whether this treatment improves outcomes and is safe to use.

Neuroendocrine tumors are difficult to treat once they have spread, and doctors need better options to help patients live longer and feel better. This trial exists to see whether adding a targeted radioactive treatment to standard therapy offers real benefits compared to simply increasing the dose of current medication.